## COMBINED DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION AND POWER OF ATTORNEY

☐ Declaration	Submitted with Initial F Submitted after Initial F ed inventor, I hereby dec	Filing (surcharge (37 CF	OR FR 1.16(e)) re	equired)			
My residence, post office address, and citizenship are as stated below next to my name. I believe I am the original, first, and sole inventor (if only one name is listed below) or an original, first, and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:							
THERAPEUTIC AGENT FOR SCHIZOPHRENIA							
the specification	of which:				* .**	·	
	is attached hereto.	aa Aa	-mlicatio- Na			اسم	
L.J	was filed on	as Aj	piicauon No <i>(if applicab</i>	 le)		and	
	was amended onwas filed by Express M and was amended onwas filed on January 7.	ail No.	(i) applicable	as Applica	ation No. not kn	iown yet,	
	and was amended on _		(if appli	icable).		• •	
$\boxtimes$	was filed on January 7.	2004 as PCT Internation	onal Applica	tion No. PO	CT/JP2004/000	023 and	
	was amended on	<del> </del>	(if any).				
I state that I have reviewed and understand the contents of the specification identified above, including the claim(s), as amended by any amendment referred to above.  I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.							
I claim foreign priority benefits under 35 USC 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application(s) designating at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application(s) for patent, utility model, design registration, inventor's or plant breeder's rights certificate(s), or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter and having a filing date before that of the application(s) from which the benefit of priority is claimed.							
Prior Foreign Application Numb		Foreign Filing Date (MM/DD/YYYY)	Priority Cl YES	laimed NO	Certified Copy A YES	Attached? NO	
001817/2003		01/08/2003	$\boxtimes$			$\boxtimes$	
		<del> :</del>					

In re Appln. of Bessho et al. Attorney Docket No. 236605

As a named inventor, I hereby appoint Leydig, Voit & Mayer, Ltd. to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: Customer Number 23460.



PATENT TRADEMARK OFFICE

I further direct that correspondence concerning this application be directed to Leydig, Voit & Mayer, Ltd.: Customer Number 23460.



\_\_...

PATENT TRADEHARK OFFICE

I declare that all statements made herein of my own knowledge are true, that all statements made on information and belief are believed to be true, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Tollioko BESSHO	
Inventor's signature <u>Tomoko</u> Bessho	
Date June 27, 2005	Country of Citizenship: Japan
Residence: Chuo-ku, Tokyo, Japan (city/state or country)	
Post Office Address	
	The Office of Avenue
(complete mailing address): c/o Mitsubishi Pharma Corporation	Tokyo Office, 2-6, Nihonbashi-honcho
2-chome, Chuo-ku, Tokyo 103-840	Japan
Full name of second joint inventor, if any: Ken TAKASHINA	
Inventor's signature Ken Tahashin	<del></del>
DateJune 27, 2005	Country of Citizenship: Japan
Residence Chuo-ku, Tokyo, Japan (city/state or country)	
Post Office Address	
(complete mailing address): c/o Mitsubishi Pharma Corporation	Tokyo Office, 2-6. Nihonbashi-honcho
2-chome Chuo-ku Tokyo 103-8405	Innan